Comparison And Development Of Immunohistochemical Diagnostic Criteria For Blastic Plasmacytoid Dendritic Cell Neoplasm.

[1]  A. Malhotra,et al.  A Real-world Perspective of CD123 Expression in Acute Leukemia as Promising Biomarker to Predict Treatment Outcome in B-ALL and AML. , 2020, Clinical lymphoma, myeloma & leukemia.

[2]  F. Jardin,et al.  How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? , 2019, Blood advances.

[3]  M. Konopleva,et al.  Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm , 2019, The American journal of surgical pathology.

[4]  M. Konopleva,et al.  Tagraxofusp in Blastic Plasmacytoid Dendritic‐Cell Neoplasm , 2019, The New England journal of medicine.

[5]  J. V. van Dongen,et al.  CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping , 2018, Cytometry. Part B, Clinical cytometry.

[6]  K. Ohshima,et al.  Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response , 2018, Leukemia.

[7]  M. Ferrer,et al.  A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm. , 2016, Cancer cell.

[8]  L. Pagano,et al.  Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches , 2016, British journal of haematology.

[9]  W. Vermi,et al.  Neoplasms derived from plasmacytoid dendritic cells , 2016, Modern Pathology.

[10]  H. Nakasone,et al.  ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern , 2016, International Journal of Hematology.

[11]  S. Perkins,et al.  Optimized immunohistochemical panel to differentiate myeloid sarcoma from blastic plasmacytoid dendritic cell neoplasm , 2014, Modern Pathology.

[12]  G. Ehninger,et al.  Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia , 2014, Blood Cancer Journal.

[13]  T. Petrella,et al.  Blastic Plasmacytoid Dendritic Cell Neoplasms: Clinico-immunohistochemical Correlations in a Series of 91 Patients , 2014, The American journal of surgical pathology.

[14]  L. Jeffrey Medeiros,et al.  TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow , 2013, American journal of hematology.

[15]  W. Vermi,et al.  BDCA-2 (CD303): a highly specific marker for normal and neoplastic plasmacytoid dendritic cells. , 2013, Blood.

[16]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[17]  T. George,et al.  Immunophenotypic analysis of myeloperoxidase-negative leukemia cutis and blastic plasmacytoid dendritic cell neoplasm. , 2012, American journal of clinical pathology.

[18]  M. Paulli,et al.  Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion. , 2011, Blood.

[19]  T. Petrella,et al.  Histologic and immunohistologic characterization of skin localization of myeloid disorders: a study of 173 cases. , 2011, American journal of clinical pathology.

[20]  E. Jaffe,et al.  Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications , 2010, Haematologica.

[21]  L. Cerroni,et al.  Cutaneous Manifestations of Blastic Plasmacytoid Dendritic Cell Neoplasm—Morphologic and Phenotypic Variability in a Series of 33 Patients , 2010, The American journal of surgical pathology.

[22]  E. Macintyre,et al.  Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia , 2009, British journal of haematology.

[23]  Y. Ishikawa,et al.  KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer , 2009, Clinical Cancer Research.

[24]  S. Pileri,et al.  Novel markers of normal and neoplastic human plasmacytoid dendritic cells. , 2008, Blood.

[25]  R. Willemze,et al.  Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. , 2007, Blood.

[26]  M. Herling,et al.  Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms , 2006, Modern Pathology.

[27]  M. Teitell,et al.  TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis. , 2004, American journal of clinical pathology.

[28]  V. Deneys,et al.  Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts , 2004, European journal of immunology.

[29]  E. Coccia,et al.  Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. , 2002, Blood.

[30]  R. Gressin,et al.  Identification of a leukemic counterpart of the plasmacytoid dendritic cells. , 2001, Blood.

[31]  A. Órfão,et al.  CD123 hiDendritic Cell Lymphoma: An Unusual Case of Non-Hodgkin Lymphoma , 1999, Annals of Internal Medicine.

[32]  T. Molina,et al.  CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Groupe Français d'Etude des Lymphomes Cutanés (GFELC). , 1999, The American journal of surgical pathology.

[33]  K. Imai,et al.  High expression of CD56 (N‐CAM) in a patient with cutaneous CD4‐positive lymphoma , 1994, American journal of hematology.

[34]  R. Gascoyne,et al.  The BCL11AXL transcription factor: its distribution in normal and malignant tissues and use as a marker for plasmacytoid dendritic cells , 2006, Leukemia.